rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    VOR
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Vor Biopharma at jefferies global healthcare conference: cash-rich push
      Nov 17Investing.comVORJEF
      Is Narrower Quarterly Loss Altering The Investment Case For Vor Biopharma Stock?
      Nov 13Yahoo FinanceVOR
      Vor Bio, RemeGen expand collaboration to add autoimmune disease therapy
      Nov 12Seeking AlphaVOR
      Vor Biopharma (VOR) Stock Looks Reasonable After a 94% Five Year Slide

      Vor Biopharma has seen a sharp swing in fortunes over the past few years, and the stock’s long slide now sits against a much stronger year to date. With that backdrop, the key issue for investors is whether the current share price is in line with what Vor Biopharma’s earnings can reasonably support. The share price has fallen 94.4% over the past 5 years, which puts a lot of weight on the question of whether today’s valuation still lines up with the business’s earnings power. Recent updates...

      Nov 6Yahoo FinanceVOR
      Stifel reiterates Vor Biopharma stock rating on trial milestone
      Nov 2Investing.comVOR
      Vor Biopharma Q3 Loss Narrows
      Oct 30Yahoo FinanceVOR
      Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
      Oct 22ReutersVOR
      William Blair Initiates Vor Biopharma at Outperform
      Oct 21Yahoo FinanceVOR
      Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus
      Oct 8Yahoo FinanceVOR
      Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
      Oct 5Yahoo FinanceVOR
      Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)

      In September 2026, Vor Biopharma reported a post hoc analysis from a China-based Phase 3 trial showing that telitacicept produced deep, durable clinical responses and was generally well tolerated over 48 weeks in adults with generalized myasthenia gravis. The analysis highlighted that most patients who reached minimal symptom expression maintained it and spent much of their remaining follow-up in this state, underscoring the therapy’s potential to meaningfully reduce daily symptom burden in...

      Oct 4Yahoo FinanceVOR
      Stifel reiterates Vor Biopharma stock rating on telitacicept potential
      Sep 28Investing.comVOR
      Vor Biopharma at Stifel 2026 forum: telitacicept pushes dual path
      Sep 23Investing.comVORSF
      Vor Biopharma: A Funded Replication Story With Franchise Potential (NASDAQ:VOR)

      Vor Biopharma is advancing telitacicept globally, leveraging strong Chinese clinical evidence and a robust liquidity position. Read why VOR stock is a buy.

      Sep 18Seeking AlphaVOR
      Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), United Therapeutics (UTHR) and Spyre Therapeutics (SYRE)

      Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailVOR
      Vor Biopharma at Citigroup’s biopharma back to school summit: pipeline push
      Sep 9Investing.comVORC
      Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

      Topline results from UPSTREAM MG’s 24-week primary endpoint remain on track for first half of 2027 Global Phase 3 ocular myasthenia gravis (oMG) registrational trial, UPSTREAM oMG, broadens telitacicept development across the myasthenia gravis (MG) spectrum; first patient dosing anticipated in the first half of 2027 BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the comple

      Sep 8Yahoo FinanceVOR
      Vor Biopharma Completes Enrollment in Phase 3 Trial of Investigational Drug for Generalized Myasthenia Gravis

      Vor Biopharma (VOR) completed enrollment in Upstream MG, a global phase 3 registrational trial evalu

      Sep 8Yahoo FinanceVOR
      Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 83,600 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 17,900 shares of Vor Bio’s common stock to 6 newly hired employees. The

      Sep 4Yahoo FinanceVOR
      Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA)

      Detailed price information for Ideaya Biosciences Inc (IDYA-Q) from The Globe and Mail including charting and trades.

      Sep 1The Globe and MailIDYAVOR
      Vor Bio To Participate in Upcoming September Conferences

      BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Forum: Fireside Chat and 1x1 Meetings Date: Tuesday, September 8th Presentation Time: 8:00AM ET Citi’s 2026 Biopharma Back to School Conference Forum: Fireside Chat and 1x1 Meetings Date: Wednesday, September 9

      Sep 1Yahoo FinanceVOR

      This is the newest page. Registered accounts read further back.